Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus

Diabetes and Vascular Disease Research

Volumn 4, Issue 2, 2007, Pages 89-102

  Hamilton, Sandra J ^a   Chew, Gerard T ^a   Watts, Gerald F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antiglycaemic agents; Antihypertensive agents; Antioxidants; Combination therapies; Diabetes; Endothelial dysfunction; Fibrates; Statins

Indexed keywords

ALPHA TOCOPHEROL; ARGININE; ASCORBIC ACID; ATORVASTATIN; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FOLIC ACID; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHODIESTERASE V; PIOGLITAZONE; PLACEBO; PROTEIN KINASE C INHIBITOR; REPAGLINIDE; SULFONYLUREA DERIVATIVE; TETRAHYDROBIOPTERIN; THIOCTIC ACID; TROGLITAZONE; UBIDECARENONE;

ADD ON THERAPY; CARDIOVASCULAR DISEASE; CELL FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIET; DRUG EFFECT; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; ESTROGEN THERAPY; EXERCISE; HUMAN; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; PERIPHERAL CIRCULATION; RANDOMIZED CONTROLLED TRIAL; RED WINE; REVIEW;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HUMANS; HYPOGLYCEMIC AGENTS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 34547483879     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2007.026     Document Type: Review

References (188)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
2. Kim J, Koh KK, Quon MJ. The union of vascular and metabolic actions of insulin in sickness and in health. Arterioscler Thromb Vasc Biol 2005;25:889-91.
3. Woodman RJ, Chew GT, Watts GF. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus : focus on lipid-regulating therapy. Drugs 2005;65:31-74.
4. Widlansky ME, Gokce N, Keaney J, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003;42:1149-60.
5. Esper R, Nordaby R, Vilarino J, Paragano A, Cacharron J, Machado R. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006;5:4-21.
6. Vita JAM, Keaney JFJ. Endothelial function: a barometer for cardiovascular risk? [Editorial]. Circulation 2002;106:640-2.
7. Levine TB, Levine AB. The endothelium and nitric oxide In: Levine TB. Metabolic syndrome and cardiovascular disease, 1st edition. Saunders Elsevier, Philadelphia PA, 2006;175-6.
8. Russo G, Leopold JA, Loscalzo J. Vasoactive substances: Nitric oxide and endothelial dysfunction in atherosclerosis. Vascul Pharmacol 2002;38:259-69.
9. Chew GT, Watts GF. Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'. QJM 2004;97:537-48.
10. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004;24:413-20.
11. Pyke KE, Tschakovsky ME. The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. J Physiol 2005;568:357-69.
12. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Kajiyama G, Oshima T. A noninvasive measurement of reactive hyperemia that can be used to assess resistance artery endothelial function in humans. Am J Cardiol 2001;87:121-5.
13. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995;25:918-23.
14. Kato MD, Shiode MD, Yamagata MD, Matsuura MD, Kajiyama MD. Coronary segmental responses to acetylcholine and bradykinin in patients with atherosclerotic risk factors. Am J Cardiol 1997;80:751-5.
15. Stehouwer CD, Stroes ES, Hackeng WH, Mulder PG, Den Ottolander GJ. von Willebrand factor and development of diabetic nephropathy in IDDM. Diabetes 1991;40:971-6.
16. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989;1:461-3.
17. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993;14:506-12.
18. Albertini JP, Valensi P, Lormeau B et al. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment. Diabetes Care 1998;21:1008-13.
19. Hwang SJP, Ballantyne CMM, Sharrett ARM et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997;96:4219-25.
20. Thorand B, Baumert J, Chambless L et al, for the MONICA/KORA Study Group. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 2006;26:398-405.
21. Lim SC, Caballero AE, Smakowski R LoGerfo FW, Horton ES, Veves A. Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care 1999;22:1865- 70.
22. Hill JM, Zalos G, Halcox JPJ et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
23. Al Suwaidi J, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-54.
24. Neunteufl T, Heher S, Katzenschlager R et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000;86:207-10.
25. Kuvin JTM, Karas RHM. Clinical utility of endothelial function testing: ready for prime time? Circulation 2003;107:3243-7.
26. Kuvin JT, Patel AR, Sliney KA et al. Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol 2001;38:1843-9.
27. Perticone F, Ceravolo R, Pujia A et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001;104:191-6.
28. Schachinger VM, Britten MBM, Zeiher AMM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
29. Chan SY, Mancini GBJ, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol 2003;42:1037-43.
30. Quyyumi AA. Prognostic value of endothelial function. Am J Cardiol 2003;91:19-24.
31. Halcox JPJ, Schenke WHB, Zalos GR et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-8.
32. Papaioannou GI, Kasapis C, Seip RL et al. Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging. J Nucl Cardiol 2006;13:362-8.
33. Nitenberg A, Pham I, Antony I, Valensi P, Attali JR, Chemla D. Cardiovascular outcome of patients with abnormal coronary vasomotion and normal coronary arteriography is worse in type 2 diabetes mellitus than in arterial hypertension: A 10 year follow-up study. Atherosclerosis 2005;183:113-20.
34. Nitenberg A, Valensi P, Sachs R, Cosson E, Attali JR, Antony I. Prognostic value of epicardial coronary artery constriction to the cold pressor test in type 2 diabetic patients with angiographically normal coronary arteries and no other major coronary risk factors. Diabetes Care 2004;27:208-15.
35. McVeigh GE, Brennan GM, Johnston GD et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35:771-6.
36. Watts GF, O'Brien SF, Silvester W, Millar JA. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci (Lond) 1996;91:567-73.
37. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996;27:567-74.
38. Enderle MD, Benda N, Schmuelling RM, Haering HU, Pfohl M. Preserved endothelial function in IDDM patients, but not in NIDDM patients, compared with healthy subjects. Diabetes Care 1998;21:271-7.
39. Henry RMA, Ferreira I, Kostense PJ et al. Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not: The Hoorn Study. Atherosclerosis 2004;174:49-56.
40. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 1993;42:1017-25.
41. Prior JO, Quinones MJ, Hernandez-Pampaloni M et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 2005;111:2291-8.
42. Guerci B, Kearney-Schwartz A, Bohme P, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Part 1: physiology and methods for exploring the endothelial function. Diabetes Metab 2001;27:425-34.
43. Papaioannou GI, Seip RL, Grey NJ et al. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-Brachial Artery Reactivity study). Am J Cardiol 2004;94:294-9.
44. Watts GF, Playford DA. Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis. Atherosclerosis 1998;141:17-30.
45. Kim J, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113:1888-904.
46. Nesto R. C-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med 2004;21:810-17.
47. Dandona P, Aljada A, Chaudhuri A, Mohanty P. Endothelial dysfunction, inflammation and diabetes. Rev Endocr & Metab Disord 2004;5:189-97.
48. Iiyama K, Nagano M, Yo Y et al. Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J 1996;132:779-82.
49. Arcaro G, Zamboni M, Rossi L et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes 1999;23:936-44.
50. Cleland SJ, Petrie JR, Small M, Elliott HL, Connell JMC. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension 2000;35:507-11.
51. Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JMC. Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996;93:1331-3.
52. Nappo F, Esposito K, Cioffi M et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: Role of fat and carbohydrate meals. J Am Coll Cardiol 2002;39:1145-50.
53. Anderson RA, Evans ML, Ellis GR et al. The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis 2001;154:475-83.
54. Anderson RA, Jones CJH, Goodfellow J. Is the fatty meal a trigger for acute coronary syndromes. Atherosclerosis 2001;159:9-15.
55. Kawano H, Motoyama T, Hirashima O et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34:146-54.
56. Shige H, Ishikawa T, Suzukawa M et al. Endothelium-dependent flow-mediated vasodilation in the postprandial state in type 2 diabetes mellitus. Am J Cardiol 1999;84:1272-4.
57. Haller H. Postprandial glucose and vascular disease. Diabet Med 1997;14(suppl 3):S50-S56.
58. Lin KY, Ito AM, Asagami TM et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002;106:987- 92.
59. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109:111-39.
60. Dandona P, Aljada A. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents. J Diabetes Complications 2004;18:91-102.
61. Hamdy O, Ledbury S, Mullooly C, Jarema C. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003;26:2119-25.
62. Maiorana A, O'Driscoll G, Cheetham C et al. The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. J Am Coll Cardiol 2001;38:860-6.
63. Green DJ, Walsh JH, Maiorana A, Best MJ, Taylor RR, O'Driscoll JG. Exercise-induced improvement in endothelial dysfunction is not mediated by changes in CV risk factors: pooled analysis of diverse patient populations. Am J Physiol Heart Circ Physiol 2003;285:H2679-H2687.
64. Green DJ, Maiorana A, O'Driscoll G, Taylor R. Effect of exercise training on endothelium-derived nitric oxide function in humans. J Physiol 2004;561:1-25.
65. Duvall WL. Endothelial dysfunction and antioxidants. Mt Sinai J Med 2005;72:71-80.
66. Ting H, Timimi F, Boles D, Creager S, Ganz P, Creager M. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97:22-8.
67. Heitzer T, Finckh B, Albers S, Krohn K, Kohlschutter A, Meinertz T. Beneficial effects of [alpha]-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001;31:53-61.
68. Anderson RA, Evans LM, Ellis GR et al. Prolonged deterioration of endothelial dysfunction in response to postprandial lipaemia is attenuated by vitamin C in Type 2 diabetes. Diabet Med 2006;23:258-64.
69. Tousoulis D, Antoniades C, Vasiliadou C et al. Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmetrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus. Heart 2007;93:244-6.
70. Antoniades C, Tousoulis D, Tountas C et al. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C. Diabet Med 2004;21:552-8.
71. Darko D, Dornhorst A, Kelly FJ, Ritter JM, Chowienczyk PJ. Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in Type II diabetes. Clin Sci 2002;103:339-44.
72. Chen H, Karne RJ, Hall G et al. High-dose oral vitamin C partially replenishes vitamin C levels in patients with type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance. Am J Physiol Heart Circ Physiol 2006;290:H137-H145.
73. Gazis A, White DJ, Page SR, Cockcroft JR. Effect of oral vitamin E (alpha-tocopherol) supplementation on vascular endothelial function in type 2 diabetes mellitus. Diabet Med 1999;16:304-11.
74. Paolisso G, Tagliamonte MR, Barbieri M et al. Chronic vitamin E administration improves brachial reactivity and increases intracellular magnesium concentration in type II diabetic patients. J Clin Endocrinol Metab 2000;85:109-15.
75. Chowienczyk PJ, Brett SE, Gopaul NK et al. Oral treatment with an antioxidant (raxofelast) reduces oxidative stress and improves endothelial function in men with type II diabetes. Diabetologia 2000;43:974-7.
76. Regensteiner JG, Popylisen S, Bauer TA et al. Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes. Vasc Med 2003;8:169-75.
77. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Keaney JF Jr, Creager MA. Oral antioxidant therapy improves endothelial function in type 1 but not type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol 2003;285: H2392-H2398.
78. Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V. Coenzyme Q10 improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 2002;45:420-6.
79. Playford DA, Watts GF, Croft KD, Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 2003;168:169-79.
80. Cordova AC, Jackson LS, Berke-Schlessel DW, Sumpio BE. The cardiovascular protective effect of red wine. JACS 2005;200:428-39.
81. Dell'Agli M, Busciala A, Bosisio E. Vascular effects of wine polyphenols. Cardiovasc Res 2004;63:593-602.
82. Napoli R, Cozzolino D, Guardasole V et al. Red wine consumption improves insulin resistance but not endothelial function in type 2 diabetic patients. Metabolism 2005;54:306-13.
83. Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 2000;43:1435-8.
84. Antoniades CM, Shirodaria CM, Warrick NB et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006;114:1193-201.
85. van Etten RW, de Koning EJ, Verhaar MC, Gaillard CA, Rabelink TJ. Impaired NO-dependent vasodilation in patients with Type II (non-insulin- dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia 2002;45:1004-10.
86. Mangoni AA, Sherwood RA, Asonganyi B, Swift CG, Thomas S, Jackson SHD. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am J Hypertens 2005;18:220-6.
87. Title LM, Ur E, Giddens K, McQueen MJ, Nassar BA. Folic acid improves endothelial dysfunction in type 2 diabetes - an effect independent of homocysteine-lowering. Vasc Med 2006;11:101-09.
88. Guerci B, Bohme P, Kearney-Schwartz A, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab 2001;27:436-47.
89. Schalkwijk CG, Stehouwer CDA. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci 2005;109:143-59.
90. Bagg W, Whalley GA, Gamble G, Drury PL, Sharpe N, Braatvedt GD. Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. Intern Med J 2001;31:322-8.
91. Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2000;20:545-50.
92. Vehkavaara S, Yki-Jarvinen H. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2004;24:325-30.
93. Gaenzer H, Neumayr G, Marschang P et al. Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus. Am J Cardiol 2002;89:431-4.
94. Rask-Madsen C, Ihlemann N, Krarup T et al. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes 2001;50:2611-18.
95. Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007;3:46-56.
96. Evans M, Anderson RA, Smith JC et al. Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus. Euro J Clin Invest 2003;33:231-8.
97. Sundaresan P, Lykos D, Daher A, Diamond T, Morris R, Howes LG. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM. Diabetes Care 1997;20:692-7.
98. Williams S, Abbott D, Morfis L, Manwaring P, Diamond T, Howes LG. Effects of glibenclamide on blood pressure and cardiovascular responsiveness in non-insulin dependent diabetes mellitus. J Hypertens 1998;16:705- 11.
99. Spallarossa P, Schiavo M, Rossettin P et al. Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia. Diabetes Care 2001;24:738-42.
100. Wascher TC, Boes U. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients. Clin Physiol Funct Imaging 2005;25:40-6.
101. Abbink EJ, Pickkers R Van Rosendaal AJ et al. Vascular effects of glibenclamide vs. glimepiride and metformin in type 2 diabetic patients. Diabet Med 2002;19:136-43.
102. Manzella D, Grella R, Abbatecola AM, Paolisso G. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care 2005;28:366-71.
103. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006;91:837-42.
104. Nystrom T, Gutniak MK, Zhang Q et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287:E1209-E1215.
105. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001;37:1344-50.
106. Natali A, Baldeweg S, Toschi E et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004;B27:1349-57.
107. Gervois P, Fruchart JC, Staels B. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab 2007;3:145-56.
108. Caballero AE, Saouaf R, Lim SC et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: A placebo-controlled randomized clinical trial. Metabolism 2003;52:173-80.
109. Suzuki M, Takamisawa I, Yoshimasa Y, Harano Y. Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. Diabetes Res Clin Pract (In press).
110. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 2005;46:773-8.
111. Satoh N, Ogawa Y, Usui T, Tagami T. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003;26:2493-9.
112. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004;27:484-90.
113. Picard S. Lipoprotein glyco-oxidation. Diabetes Metab 1995;21:89-94.
114. Dart AM, Chin-Dusting JPF. Lipids and the endothelium. Cardiovasc Res 1999;43:308-22.
115. Mackness MI, Durrington PN, Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol 2000;11:383-8.
116. Calabresi L, Gomaraschi M, Franceschini C. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 2003;23:1724-31.
117. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
118. Stroes ESG, Koomans HA, Rabelink TJ, de Bruin TWA. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995;346:467-71.
119. O'Driscoll GMBB, Green DP, Taylor RRM. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31.
120. van de Ree MA, Huisman MV, de Man FH, van der Vijver JC, Meinders AE, Blauw GJ. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res 2001;52:299-305.
121. van Etten RW, de Koning EJ, Honing ML, Stroes ES, Gaillard CA, Rabelink TJ. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2002;22:799-804.
122. Sheu WH, Juang BL, Chen YT, Lee WJ. Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia. Diabetes Care 1999;22:1224-5.
123. Sheu WH-H, Chen YT, Lee WJ. Improvement in endothelial dysfunction with LDL cholesterol level <80 mg/dl in type 2 diabetic patients. Diabetes Care 2001;24:1499-501.
124. Tsunekawa T, Hayashi T, Kano H et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001;104:376-9.
125. Tan KCB, Chow WS, Tam SCF, Ai VHG, Lam CHL, Lam KSL. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002;87:563-8.
126. Ceriello A, Taboga C, Tonutti L et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002;106:1211-18.
127. Ceriello A, Assaloni R, Da Ros R et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005;111:2518-24.
128. Economides PA, Caselli A, Tiani E, Khaodhiar L, Horton ES, Veves A. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 2004;89:740-7.
129. Beishuizen ED, Tamsma JT, Jukema JW et al. The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2005;28:1668-74.
130. van Venrooij FV, van de Ree MA, Bots ML, Stolk RP, Huisman MV, Banga JD. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2002;25:1211-16.
131. Balletshofer BM, Goebbel S, Rittig K et al. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes. Exp Clin Endocrinol Diabetes 2005;113:324-30.
132. Tantikosoom W, Thinkhamrop B, Kiatchusakul S, Jarernsiripornkul N, Srinakarin J, Ojongpian S. Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level. J Med Assoc Thai 2005;88:399-406.
133. Tran D, Lowy A, Howes JB, Howes LG. Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men. Diabetes Obes Metab 2005;7:273-81.
134. Avogaro A, Miola M, Favaro A et al. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur J Clin Invest 2001;31:60309.
135. Playford DA, Watts GF, Best JD, Burke V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol 2002;90:1254-7.
136. Evans M, Anderson RA, Graham J et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000;101:1773-9.
137. Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 2006;9:95-104.
138. McVeigh GE, Brennan GM, Johnston GD et al. Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993;36:33-8.
139. Woodman RJ, Mori TA, Burke V et al. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 2003;166:85-93.
140. West SG, Hecker KD, Mustad VA et al. Acute effects of monounsaturated fatty acids with and without omega-3 fatty acids on vascular reactivity in individuals with type 2 diabetes. Diabetologia 2005;48:113-22.
141. Hilpert KF, West SG, Kris-Etherton PM, Hecker KD, Simpson NM, Alaupovic P. Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes. Am J Clin Nutr 2007;85:369-76.
142. Mori TA, Watts GF, Burke V, Hilme E, Puddey IB, Beilin LJ. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 2000;102:1264-9.
143. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin- aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005;16:120-6.
144. de Gasparo M. Angiotensin II and nitric oxide interaction. Heart Fail Rev 2002;7:347-58.
145. Leiter LA, Lewanczuk RZ. Of the renin-angiotensin system and reactive oxygen species: type 2 diabetes and angiotensin II inhibition. Am J Hypertens 2005;18:121-8.
146. Li J, Zhao SP, Li XP, Zhuo QC, Gao M, Lu SK. Non-invasive detection of endothelial dysfunction in patients with essential hypertension. Int J Cardiol 1997;61:165-9.
147. Ma L, Zhao S, Li J, Zhou Q, Gao M. Interaction of hypertension and diabetes on impairment of endothelial function. Chin Med J (Engl) 2001;114:563-7.
148. Bijlstra PJ, Smits P, Lutterman JA, Thien T. Effect of long-term angiotensin-converting enzyme inhibition on endothelial function in patients with the insulin-resistance syndrome. J Cardiovasc Pharmacol 1995;25:658-64.
149. Hermann TS, Li W, Dominguez H et al. Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:1001-08.
150. O'Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999;33:1506-11.
151. Cheetham C, Collis J, O'Driscoll G, Stanton K, Taylor R, Green D. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 2000;36:1461-6.
152. Cheetham C, O'Driscoll G, Stanton K, Taylor R, Green D. Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in type II diabetes. Clin Sci 2001;100:13-17.
153. Flammer AJ, Hermann F, Wiesli P et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 2007;25:785- 91.
154. Davies JI, Band M, Morris A, Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 2004;47:1687-94.
155. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198- 202.
156. Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004;64:137-51.
157. Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med 2000;247:563-9.
158. Derosa G, Cicero AEG, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther 2004;26:1599-607.
159. Muhlestein JB, May HT, Jensen JR et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006;48:396-401.
160. Koh KK, Quon MJ, Han SH et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005;45:1649-53.
161. Fegan PG, Shore AC, Mawson D, Tooke JE, MacLeod KM. Microvascular endothelial function in subjects with type 2 diabetes and the effect of lipid-lowering therapy. Diabet Med 2005;22:1670-6.
162. Jones PH. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus. Am J Cardiol 2007;99:133-40.
163. Robins SJ, Bloomfield HE. Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol 2006;17:431-9.
164. Koh KK, Quon MJ, Han SH et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005;45:1088-93.
165. Martin-Ventura JL, Tunon J, Duran MC, Blanco-Colio LM, Vivanco F, Egido J. Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients. J Am Soc Nephrol 2006;17:S189-S193.
166. Koh KK, Quon MJ, Han SH, Ahn JY, Lee Y, Shin EK. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1 + 2 in patients with type 2 diabetes. Atherosclerosis (In press).
167. Jukema JW, Zwinderman AH, van Boven AJ et al. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. Arterioscler Thromb Vasc Biol 1996;16:425-30.
168. Fogari R, Derosa G, Lazzari P et al. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens 2004;17:823-7.
169. Jukema JW, Ad JvB, Aeilko HZ, Arnoud VdL, Albert VGB. Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis. Cardiovasc Drugs Ther 1998;12:111-18.
170. Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baum H, Quinn PJ. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993;46:1055-7.
171. Shepherd J, Betteridge J, Van Gaal L. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin 2005;21:665-82.
172. Van JT, Pan J, Wasty T, Chan E, Wu X, Charles MA. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am J Cardiol 2002;89:1306-08.
173. Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002;144:165-72.
174. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004;95:764-72.
175. Shaul PW. Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J Physiol 2003;547:21-33.
176. Simons L, Tonkon M, Masana L et al. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin 2004;20:1437-45.
177. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca V. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002;25:1336-9.
178. Rosano GMC, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:214-22.
179. Hulley SM, Grady DM, Bush TP, Furberg CM, Herrington DM, Riggs BM, Vittinghoff EP. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
180. Manson JE, Hsia J, Johnson KC et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.
181. Rubanyi GM, Johns A, Kauser K. Effect of estrogen on endothelial function and angiogenesis. Vascul Pharmacol 2002;38:89-98.
182. Lee SJ, Lee DW, Kim KS, Lee IK. Effect of estrogen on endothelial dysfunction in postmenopausal women with diabetes. Diabetes Res Clin Pract 2001;54:S81-S92.
183. Koh KK, Kang MH, Jin DK et al. Vascular effects of estrogen in type II diabetic postmenopausal women. J Am Coll Cardiol 2001;38:1409-15.
184. Silvestri A, Gambacciani M, Vitale C et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas 2005;50:305-11.
185. Howes JB, Tran D, Brillante D, Howes LG. Effects of dietary supplementation with isoflavones from red clover on ambulatory blood pressure and endothelial function in postmenopausal type 2 diabetes. Diabetes, Obes Metab 2003;5:325-32.
186. Bilsborough W, O'Driscoll G, Stanton K et al. Effect of lowering tumour necrosis factor-alpha on vascular endothelial function in type II diabetes. Clin Sci 2002;103:163-9.
187. Butler R, Morris AD, Belch JJF, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000;35:746-51.
188. Katusic ZS. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol 2001;281:H981-H986.